Darmiyan is a developer of brain diagnostics that is creating a novel quantitative virtual microscopy for early detection of Alzheimer's disease from non-invasive MRI.
Darmiyan is developing a commercial diagnostic software platform for the early detection, monitoring and stratification of Alzheimer’s disease (AD) and other neurodegenerative disorders through an innovative magnetic resonance (MR) image analysis technology.
Darmiyan was founded in 2016 by Padideh Kamali-Zare, Kaveh Vejdani, and Thomas Liebmann. The company is headquartered in San Francisco, California.
Darmiyan's flagship product BrainSee, a novel and proprietary technology (US patent 10573414), provides the long-awaited solution for early diagnosis, monitoring, and stratification of Alzheimer's disease. BrainSee's AI-powered algorithm takes the currently available standard clinical brain MRI and basic cognitive tests and generates brain maps and scores that indicate pathology at the earliest stages of the disease when treatments are feasible.
Darmiyan is backed by Y-Combinator, Eisai, IT-Farm, and others. The company raised $6M in a Seed round on April 10, 2020. This brings Darmiyan's total funding to $10.5M to date. Darmiyan has won numerous awards and recognitions including the TEDMED Hive Innovator in 2018 and CABHI's I2P2 & innovation awards in 2018 & 2019, respectively.